A Randomized, Double-blind, Positive-controlled Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01E (A COVID-19 Alpha/Beta/Delta/Omicron Variants S-Trimer Vaccine) in Adolescents Aged 12-17 Years and Previously Fully Vaccinated With mRNA COVID-19 Vaccine
Latest Information Update: 04 Apr 2024
At a glance
- Drugs SCTV 01E (Primary) ; Elasomeran
- Indications COVID 2019 infections
- Focus Pharmacodynamics
- Sponsors Sinocelltech
Most Recent Events
- 03 May 2022 New trial record